The agency’s decision supports broader access to a minimally invasive treatment for patients with severe tricuspid ...

CroíValve announced today that it received new funding from Horizon Europe’s European Innovation Council (EIC) Accelerator ...

The FDA approved the Evoque tricuspid valve replacement system as the first transcatheter treatment for tricuspid regurgitation (TR), Edwards Lifesciences announced. Evoque gained an indication ...

Right-heart valve deterioration traced to pacing type, revealing distinct tricuspid vulnerability with right-ventricular lead placement.

PHOENIX -- Tricuspid regurgitation (TR) at baseline was linked to poorer outcomes after percutaneous mitral valve repair and didn't improve for most patients afterward, two registry studies showed.

Here at the New York Valves meeting, hosted by the Cardiovascular Research Foundation, panelists mulled over the options: either transvenous lead extraction or entrapment ("jailing") of the lead by ...

At two years of follow-up, patients with a poorly functioning tricuspid valve in the heart who received the best available medical therapy plus a minimally invasive procedure using a clip to ...

Joan Mertz, 83, became the first patient in the state to undergo an artificial heart valve replacement without the need for open-heart surgery.

Severe tricuspid regurgitation is associated with disabling symptoms and an increased risk of death. Data regarding outcomes after percutaneous transcatheter tricuspid-valve replacement are needed.

Edwards Lifesciences Corporation today announced the company's EVOQUE tricuspid valve replacement system has received Health Canada's approval for the treatment of tricuspid regurgitation (TR ...